首页> 外文期刊>Nutrients >Effect of a Synbiotic Containing Lactobacillus paracasei and Opuntia humifusa on a Murine Model of Irritable Bowel Syndrome
【24h】

Effect of a Synbiotic Containing Lactobacillus paracasei and Opuntia humifusa on a Murine Model of Irritable Bowel Syndrome

机译:含有Synbiotic含乳杆菌和仙飞雀Humifusa对肠易激综合征鼠模型的影响

获取原文
           

摘要

The administration of a combination of probiotics and prebiotics is expected to be a promising strategy for improving irritable bowel syndrome (IBS) symptoms. This study aimed to investigate the efficacy of a synbiotic containing Lactobacillus paracasei and Opuntia humifusa extract for symptomatic improvement of IBS in a murine model and to evaluate the mechanism underlying the beneficial effects of this synbiotic. A total of 20 male Wistar rats aged 8 weeks with IBS induced by restraint stress were assigned into four groups and administered L. paracasei as a probiotic and O. humifusa extract as a prebiotic for 4 weeks. The primary outcome was stool consistency at week 4. To evaluate the mechanism underlying the beneficial effects of the synbiotic, fecal microbial analysis was conducted, and the serum corticosterone levels, tumor necrosis factor-α (TNF-α) levels in the colon tissue, and expression of tight junction proteins were investigated. All three treatment groups showed significantly lower scores for stool consistency than the control group at week 4 (all p 0.001). When compared with the control group, the synbiotic groups showed a significantly greater abundance of L. paracasei in fecal microbial analysis, lower serum corticosterone levels, lower TNF-α levels in the colon tissue, and higher expression of tight junction proteins. This novel synbiotic containing L. paracasei and O. humifusa extract can improve the stool consistency in a murine model of IBS. It may be a promising treatment option for IBS, and human studies are warranted.
机译:预计益生菌和益生元组合的给药是一种提高肠易激综合征(IBS)症状的有希望的策略。本研究旨在探讨含有乳酸乳杆菌和Ipuntia humifusa提取物的同步乳酸乳杆菌和Ipuntia Humifusa提取物的疗效,并评估该同步患者的有益效果的机制。通过约束应激引起的IBS诱导的IBS共20岁的20只雄性Wistar大鼠分配到四组,并作为益生菌和O. humifusa提取物作为益生元4周给予4周。主要结果是第4周的稳定一致性。为了评估所作机制,进行粪便微生物分析的有益效果,血清皮质酮水平,结肠组织中的肿瘤坏死因子-α(TNF-α)水平,研究了紧密结蛋白的表达。所有三个治疗组在第4周(所有P <0.001)的对照组,粪便一致性显着降低。与对照组相比,Syciotic基团在粪便微生物分析中显示出明显较大的L.帕拉卡酶,降低血清皮质酮水平,降低结肠组织中的TNF-α水平,以及紧密结蛋白的表达更高。这种含有L. paracaCyi和O. Humifusa提取物的新型Synbiotic可以改善IBS的鼠模型中的粪便一致性。它可能是IBS的有希望的治疗选择,并保证人类研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号